These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 8269292

  • 1. Drug therapy for torsade de pointes.
    Banai S, Tzivoni D.
    J Cardiovasc Electrophysiol; 1993 Apr; 4(2):206-10. PubMed ID: 8269292
    [Abstract] [Full Text] [Related]

  • 2. A practical approach to torsade de pointes.
    Roden DM.
    Clin Cardiol; 1997 Mar; 20(3):285-90. PubMed ID: 9068917
    [Abstract] [Full Text] [Related]

  • 3. Drug-induced torsade de pointes.
    Raehl CL, Patel AK, LeRoy M.
    Clin Pharm; 1985 Mar; 4(6):675-90. PubMed ID: 2416504
    [Abstract] [Full Text] [Related]

  • 4. Torsade de pointes.
    Roden DM.
    Clin Cardiol; 1993 Sep; 16(9):683-6. PubMed ID: 7902224
    [Abstract] [Full Text] [Related]

  • 5. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone.
    Hii JT, Wyse DG, Gillis AM, Duff HJ, Solylo MA, Mitchell LB.
    Circulation; 1992 Nov; 86(5):1376-82. PubMed ID: 1423949
    [Abstract] [Full Text] [Related]

  • 6. [Efficacy of isoproterenol, magnesium sulfate and verapamil for torsade de pointes].
    Yamamoto H, Bando S, Nishikado A, Hamai K, Yamamoto K, Shinohara A.
    Kokyu To Junkan; 1991 Mar; 39(3):261-5. PubMed ID: 2047605
    [Abstract] [Full Text] [Related]

  • 7. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
    Lentini S, Rao ML, Schröder R, Lüderitz B, Bauriedel G.
    Dtsch Med Wochenschr; 2001 Dec 07; 126(49):1396-400. PubMed ID: 11740632
    [Abstract] [Full Text] [Related]

  • 8. Drug-induced torsade de pointes. Incidence, management and prevention.
    Faber TS, Zehender M, Just H.
    Drug Saf; 1994 Dec 07; 11(6):463-76. PubMed ID: 7727055
    [Abstract] [Full Text] [Related]

  • 9. Antiarrhythmic drugs and torsade de pointes.
    Lazzara R.
    Eur Heart J; 1993 Nov 07; 14 Suppl H():88-92. PubMed ID: 8293758
    [Abstract] [Full Text] [Related]

  • 10. [Iatrogenic torsade de pointes induced by thioridazine].
    Paoloni P, Ciliberti D, Blasi N, Capone P.
    Minerva Cardioangiol; 1992 Jun 07; 40(6):245-9. PubMed ID: 1407620
    [Abstract] [Full Text] [Related]

  • 11. The use of isoproterenol and phenytoin to reverse torsade de pointes.
    Omar HR, Sprenker C, Karlnoski R, Mangar D, Camporesi EM.
    Am J Emerg Med; 2014 Jun 07; 32(6):683.e5-7. PubMed ID: 24462399
    [Abstract] [Full Text] [Related]

  • 12. Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.
    Skanes AC, Morton BC, Green MS, Tang AS.
    Can J Cardiol; 1997 Apr 07; 13(4):383-6. PubMed ID: 9141970
    [Abstract] [Full Text] [Related]

  • 13. Torsade de pointes with sotalol overdose treated successfully with lidocaine.
    Assimes TL, Malcolm I.
    Can J Cardiol; 1998 May 07; 14(5):753-6. PubMed ID: 9627533
    [Abstract] [Full Text] [Related]

  • 14. Treatment of torsade de pointes with intravenous magnesium in idiopathic long QT syndrome.
    Hasegawa J, Takami T, Kaneda T, Yamane W, Hoshio A, Igawa O, Fujimoto Y, Kotake H, Mashiba H.
    Jpn Circ J; 1991 Nov 07; 55(11):1057-60. PubMed ID: 1749066
    [Abstract] [Full Text] [Related]

  • 15. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.
    Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH.
    JAMA; 1993 Dec 01; 270(21):2590-7. PubMed ID: 8230644
    [Abstract] [Full Text] [Related]

  • 16. Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes.
    Chézalviel-Guilbert F, Davy JM, Poirier JM, Weissenburger J.
    J Am Coll Cardiol; 1995 Sep 01; 26(3):787-92. PubMed ID: 7642874
    [Abstract] [Full Text] [Related]

  • 17. Torsade de pointes: the clinical considerations.
    Gowda RM, Khan IA, Wilbur SL, Vasavada BC, Sacchi TJ.
    Int J Cardiol; 2004 Jul 01; 96(1):1-6. PubMed ID: 15203254
    [Abstract] [Full Text] [Related]

  • 18. Terminology of torsades de pointes.
    Tzivoni D, Keren A, Banai S, Stern S.
    Cardiovasc Drugs Ther; 1991 Apr 01; 5(2):505-7. PubMed ID: 1854659
    [Abstract] [Full Text] [Related]

  • 19. QT interval prolongation, torsade de pointes and renal disease.
    Patanè S, Marte F, Di Bella G, Currò A, Coglitore S.
    Int J Cardiol; 2008 Nov 12; 130(2):e71-3. PubMed ID: 18255176
    [Abstract] [Full Text] [Related]

  • 20. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients.
    Kay GN, Plumb VJ, Arciniegas JG, Henthorn RW, Waldo AL.
    J Am Coll Cardiol; 1983 Nov 12; 2(5):806-17. PubMed ID: 6630761
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.